Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally.

Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH, Anwer K.

J Gene Med. 2009 Aug;11(8):718-28. doi: 10.1002/jgm.1356.

PMID:
19507172
2.

A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.

Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H, Matar MM, Fewell JG, Anwer K, Lesniak MS.

Anticancer Drugs. 2008 Feb;19(2):133-42. doi: 10.1097/CAD.0b013e3282f24017.

PMID:
18176109
4.

Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.

O'Malley BW Jr, Li D, McQuone SJ, Ralston R.

Laryngoscope. 2005 Mar;115(3):391-404.

PMID:
15744147
5.

Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer.

Janát-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW.

Anticancer Res. 2006 Sep-Oct;26(5A):3223-8.

6.

Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma.

Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr.

Arch Otolaryngol Head Neck Surg. 2001 Nov;127(11):1319-24.

PMID:
11701067
7.
8.

Combination nonviral cytokine gene therapy for head and neck cancer.

Li D, Zeiders JW, Liu S, Guo M, Xu Y, Bishop JS, O'Malley BW Jr.

Laryngoscope. 2001 May;111(5):815-20.

PMID:
11368072
9.

IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.

Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE.

J Immunol. 1999 Dec 15;163(12):6378-85.

10.

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71.

12.

Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.

Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ.

Clin Cancer Res. 2009 Apr 1;15(7):2323-34. doi: 10.1158/1078-0432.CCR-08-2039. Epub 2009 Mar 24.

13.

Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment.

Janát-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M, Kim SW.

J Control Release. 2005 Jan 3;101(1-3):273-85.

PMID:
15588911
14.

Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.

Ozols RF.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S60-73. Review.

PMID:
19780247
15.
16.

Effective transfer of interleukin-12 gene to solid tumors using a novel gene delivery system, poly [D,L-2,4-diaminobutyric acid].

Iwashita Y, Ogawa T, Goto S, Nakanishi M, Goto T, Kitano S.

Cancer Gene Ther. 2004 Feb;11(2):103-8.

PMID:
14671674
17.

Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.

Choi EK, Kim SW, Nam EJ, Paek J, Yim GW, Kang MH, Kim YT.

Reprod Sci. 2011 Aug;18(8):763-71. doi: 10.1177/1933719111398142. Epub 2011 Mar 18.

PMID:
21421899
18.

Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.

Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, Ikebuchi Y, Sakata M, Tasaka K, Murata Y.

Cancer Res. 2005 Jan 15;65(2):540-5.

19.

Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma.

Dickson PV, Hamner JB, Burger RA, Garcia E, Ouma AA, Kim SU, Ng CY, Gray JT, Aboody KS, Danks MK, Davidoff AM.

J Pediatr Surg. 2007 Jan;42(1):48-53.

PMID:
17208540
20.

Interferon-beta gene therapy improves survival in an immunocompetent mouse model of carcinomatosis.

Hendren SK, Prabakaran I, Buerk DG, Karakousis G, Feldman M, Spitz F, Menon C, Fraker DL.

Surgery. 2004 Apr;135(4):427-36.

PMID:
15041967

Supplemental Content

Support Center